Blockbusters in waiting: drug launches to watch in 2020New drugs for breast cancer, lymphoma, multiple sclerosis and migraine are among new product launches this year that Share XBlockbusters in waiting: drug launches to watch in 2020https://pharmaphorum.com/news/blockbusters-in-waiting-drug-launches-to-watch-in-2020/
FDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlineSpeculators who bought into a risky three-drug bet are still on track for a payout following Celgene’s merger Share XFDA to fast-track review of BMS’ CAR-T, ahead of shareholder deadlinehttps://pharmaphorum.com/news/fda-to-fast-track-review-of-bms-car-t-ahead-of-shareholder-deadline/
FDA sets August action date for Seattle’s oral HER2 drug tucatinibSeattle Genetics is a few months away from having its third drug product on the market, after the Share XFDA sets August action date for Seattle’s oral HER2 drug tucatinibhttps://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/
NICE rejects MSD/Pfizer’s combination in untreated kidney cancerNICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) Share XNICE rejects MSD/Pfizer’s combination in untreated kidney cancerhttps://pharmaphorum.com/news/nice-rejects-msd-pfizers-combination-in-untreated-kidney-cancer/
Seattle Genetics says data backs Padcev combo for first-line bladder cancerSeattle Genetics and Astellas’ new drug for relapsed bladder cancer – Padcev – could move up the treatment Share XSeattle Genetics says data backs Padcev combo for first-line bladder cancerhttps://pharmaphorum.com/news/seattle-genetics-says-data-backs-padcev-combo-for-first-line-bladder-cancer/
Xtandi takes fight to prostate cancer rivals with survival dataPfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend Share XXtandi takes fight to prostate cancer rivals with survival datahttps://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/
FDA to quickly review Novartis’ capmatinib in rare lung cancerThe FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung Share XFDA to quickly review Novartis’ capmatinib in rare lung cancerhttps://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/
Gilead closes in on second CAR-T approval in USThe FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Share XGilead closes in on second CAR-T approval in UShttps://pharmaphorum.com/news/gilead-closes-in-on-second-car-t-approval-in-us/
Boosted by Celgene’s cash, BMS bounces back after mega-mergerBristol-Myers Squibb’s $74 billion mega-merger with Celgene seems to have been vindicated after a set of glowing full-year Share XBoosted by Celgene’s cash, BMS bounces back after mega-mergerhttps://pharmaphorum.com/news/bms/
Nearly half of doctors did not discuss trials with cancer patients – surveyAlmost half of cancer patients reported that their medical care team did not discuss clinical trials with them, Share XNearly half of doctors did not discuss trials with cancer patients – surveyhttps://pharmaphorum.com/news/nearly-half-of-doctors-did-not-discuss-trials-with-cancer-patients-survey/
Calibr and AbbVie’s switchable cancer CAR-T begins clinical trialsCalifornia biotech Calibr and research partner AbbVie have clearance to start clinical trials of a new CAR-T technology, Share XCalibr and AbbVie’s switchable cancer CAR-T begins clinical trialshttps://pharmaphorum.com/news/calibr/
BMS plans another tack as EU regulators knock back lung cancer comboBristol-Myers Squibb has withdrawn a European filing of its immunotherapy combination of Opdivo and Yervoy in first line Share XBMS plans another tack as EU regulators knock back lung cancer combohttps://pharmaphorum.com/news/bms-withdraws-eu-filing-for-opdivoyervoy-in-nsclc/
Draper aims to improve AI lung cancer detection systemsUS firm Draper has announced it is aiming to make artificial intelligence (AI) systems more adept at detecting Share XDraper aims to improve AI lung cancer detection systemshttps://pharmaphorum.com/news/draper-aims-to-improve-lung-cancer/
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinibEli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter Share XLilly keeps ahead of Blueprint with swift FDA review for selpercatinibhttps://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
Roche fights off biosimilar competition as new medicines’ sales soarRoche has seen its pharmaceutical sales increase in 2019 as it fought off the impact of cheaper near-copies Share XRoche fights off biosimilar competition as new medicines’ sales soarhttps://pharmaphorum.com/news/roche-fights-off-biosimilar-competition-as-new-medicines-sales-soar/
